Beta Bionics, Inc.
NASDAQ:BBNXMedical - Equipment & Services
+$0.42 today
- Market cap
- $644.70M
- Beta
- 3.39
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$1.50
Volume 1.38M
Average 0.99M
BBNX Total Current Liabilities
All obligations due within one year.
Beta Bionics, Inc.NASDAQ: BBNX
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities rises 40.6% from a year ago
Total current liabilities stood at $23.19M at the end of Q1 FY2026, up 40.6% from a year earlier and down 25.0% from the prior quarter. Over 3 fiscal years it compounded at +51.6% a year.
Context
- Total current liabilities amounted to 7.6% of total assets at the end of Q1 FY2026, up 2.7 pp from a year earlier.
- Total current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +40.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 30.92M USD
- Year-over-year change
- +46.2%
- 3-year CAGR
- +51.6%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 30.92M | +46.2% |
| FY2024 | 2024-12-31 | 21.15M | +99.4% |
| FY2023 | 2023-12-31 | 10.61M | +19.5% |
| FY2022 | 2022-12-31 | 8.87M | — |
Total Current Liabilities vs competitors
How BBNX compares with its peers on the latest reported figures
- Peers report in different currencies, so total current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +40.6% is the 2nd highest of 7, against a peer median of +0.6%.
- Total current liabilities amounts to 7.6% of total assets for BBNX, versus a peer median of 21.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | DKK 239.08B DKK | +15.2% | +21.3% | 40.2% | |
| Jun 2026 | $2.36B USD | -28.7% | +5.2% | 36.5% | |
MMEDMiniMed Group, Inc. Common Stock | Jul 2026 | $782M USD | — | — | 16.6% |
| Jun 2026 | $744.2M USD | -26.3% | +23.1% | 23.5% | |
| Mar 2026 | $247.96M USD | -14.0% | +13.7% | 21.5% | |
| Mar 2026 | $134.56M USD | +16.1% | +36.5% | 18.1% | |
| Mar 2026 | $23.19M USD | +40.6% | +51.6% | 7.6% | |
| Mar 2026 | $10.56M USD | +92.3% | +49.2% | 3.9% | |
| Peer median (excluding BBNX) | — | +0.6% | +22.2% | 21.5% | |
Competitors are the stored peer set for BBNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Beta Bionics, Inc.
NASDAQ:BBNX
Intrinsic Alpha fair value
Locked
Current Price
$14.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.